This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (10)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Randomized Controlled Trial  • Retinal/ Chorioretinal Disorders  • Ophthalmological Procedures, Other  • Alert me on articles by topic

Arthur J. Mueller, MD, PhD; Aljoscha S. Neubauer, MD; Ulrich Schaller, MD; Anselm Kampik, MD, PhD; for the European Assessment Group for Lysis in the Eye

Arch Ophthalmol. 2003;121:1377-1381.

Objectives  To determine the effect of commonly used minimally invasive treatments for clinically complete nonarteritic central retinal artery occlusion (CRAO) and design a prospective randomized trial to evaluate selective intra-arterial lysis for this condition.

Methods  In this retrospective noncomparative case series, all medical records of patients with a diagnosis of CRAO treated at the Department of Ophthalmology, Ludwig-Maximilians-Universität, Munich, Germany, from 1994 through 1999 were reviewed for treatments administered and course of visual acuity.

Main Outcome Measures  Best-corrected visual acuity (BCVA) at initial and last visit.

Results  We identified 102 patient medical records; 71 were suitable for further analysis. Forty-four (62%) of the 71 patients included were treated with oral acetylsalicylate; 44 (62%), with oral acetazolamide; 32 (45%), with ocular massage; 22 (31%), with isovolemic hemodilution; 19 (27%), with oral pentoxifylline; 8 (11%), with topical -blocker; 6 (8%), with paracentesis of the anterior chamber; 4 (6%), with subcutaneous heparin. A mean ± SD number of treatments of 2.5 ± 1.4 was administered per patient, and BCVA increased by a mean ± SD number of Snellen lines of 0.7 ± 2.8. The BCVA in 11 patients (15%) increased by 3 or more lines. Multivariate stepwise regression did not reveal any single or combination treatment as a significant factor for improvement in BCVA. Patient age and duration of visual impairment before initial examination were not significant predictors of final BCVA.

Conclusions  Commonly used minimally invasive treatments of CRAO do not improve the natural course of the disease. A prospective trial by the European Assessment Group for Lysis in the Eye is under way to evaluate selective intra-arterial lysis, and in this trial some of these minimally invasive treatments are used in the control group.

From the Department of Ophthalmology, Ludwig-Maximilians-Universität, Munich, Germany. The authors have no relevant interest in this article.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Local Intraarterial Fibrinolysis Administered in Aliquots for the Treatment of Central Retinal Artery Occlusion: The Johns Hopkins Hospital Experience
Aldrich et al.
Stroke 2008;39:1746-1750.
ABSTRACT | FULL TEXT  

Intra-arterial thrombolysis for central retinal artery occlusion
Hayreh
Br. J. Ophthalmol. 2008;92:585-587.
FULL TEXT  

Intra-arterial thrombolysis for central retinal artery occlusion: a systematic review
Noble et al.
Br. J. Ophthalmol. 2008;92:588-593.
ABSTRACT | FULL TEXT